SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurogen (NRGN)
An SI Board Since June 1996
Posts SubjectMarks Bans Symbol
523 35 0 NRGN
Emcee:  Terry McCormick Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
398>>None expected (maybe only few) that this will work.<< True, at lekeokalani'nui-6/15/2004
397None expected (maybe only few) that this will work. Press Release Source: NeuroMiljenko Zuanic-6/15/2004
396Moving forward, Research Milestone. Within thirty (30) days of the earlier to oMiljenko Zuanic-5/27/2004
395<i>Rip off! Somebody else has got to have receptor/method IP.</i> keokalani'nui-5/6/2004
394Neurogen Corporation Announces First Quarter 2004 Financial Results and Updates mopgcw-5/5/2004
393J. Clin. Invest. 113:1344-1352 (2004). doi:10.1172/JCI200420449. Copyright ©Miljenko Zuanic-5/3/2004
392Wow. Congrats to NRGN. BTW, Baker Brothers also took down a slug. They alreadkeokalani'nui-3/19/2004
391I just wish the price were better. I'm sure they do too, but what can you dorkrw-3/19/2004
390Pretty exciting that Pincus is buying $100MM of stock at $7 in private placementMadharry-3/19/2004
389Am J Pathol. 2004 Mar;164(3):849-59. Related Articles, Links C5a-induced gekeokalani'nui-3/12/2004
388Not much on pipeline update! Press Release Source: Neurogen Corporation NeuroMiljenko Zuanic-3/8/2004
387no message. eom.keokalani'nui-1/13/2004
386Neurogen Reports Phase IIa Clinical Trial Results for Oral Asthma Drug Tuesday Jnigel bates-1/13/2004
385Press Release Source: Neurogen Corporation Neurogen Announces Milestone PaymenMiljenko Zuanic-12/23/2003
384Th's NRGN, I was bit concerned with different media reports, and someone wasMiljenko Zuanic-12/8/2003
383J. Clin. Invest. 112:1644-1654 (2003). doi:10.1172/JCI200318817. Copyright ©Miljenko Zuanic-12/5/2003
382Jim, Dietz projection is from history of this deal type, late stage preclinicalMiljenko Zuanic-12/3/2003
381Miljenko, This article cites an analyst with high single digit royalty est. Whatrkrw-12/3/2003
380<<It occurred to me that MRK might have the best chance of productive partMiljenko Zuanic-12/2/2003
379Wow! No wonder a somewhat similar company, NTII, was also feeling feisty today. Doc Bones-12/2/2003
378Not a bad deal for early preclinical candidate!Miljenko Zuanic-12/1/2003
377good for NRGN! this should give them at least a few more years..... (unfortunatephbolton-12/1/2003
37607:16 NRGN Neurogen and Merck form research alliance (6.38 ) Co and Merck (Doc Bones-12/1/2003
375From Yahoo on cc, I have not listened to the call myself so no opinion on represmopgcw-11/12/2003
374Blood, 15 November 2003, Vol. 102, No. 10, pp. 3702-3710. Prepublished online asMiljenko Zuanic-11/3/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News